




RealRate

## PHARMACEUTICAL 2021

### GENEREX BIOTECHNOLOGY CORP Rank 296 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



## PHARMACEUTICAL 2021

### GENEREX BIOTECHNOLOGY CORP Rank 296 of 409

The relative strengths and weaknesses of GENEREX BIOTECHNOLOGY CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GENEREX BIOTECHNOLOGY CORP compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 354% points. The greatest weakness of GENEREX BIOTECHNOLOGY CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 160% points.

The company's Economic Capital Ratio, given in the ranking table, is -299%, being 55% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	1,255
Cost of Goods Sold	0
Intangible Assets	43,855
Liabilities, Current	41,371
Liabilities, Non-Current	0
Other Assets	60
Other Compr. Net Income	0
Other Expenses	12,587
Other Liabilities	11,896
Other Net Income	-1,640
Property and Equipment	214
Research and Development	2,106
Revenues	0
Selling, General and Administrative Expense	17,898

Output Variable	Value in 1000 USD
Assets	45,383
Liabilities	53,267
Expenses	32,592
Stockholders Equity	-7,884
Net Income	-34,232
Comprehensive Net Income	-34,232
Economic Capital Ratio	-299%

